Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

By afschroeder • August 13, 2025

van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits J, Drakaki A, Mar N, Maroto Rey JP, Vulsteke C, Arafat W, Duran I, Dawson NA, Swami U, Gorla S, Moreno BH, Yu X, Lu YT, Bedke J. Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open. 2025 Aug 11;10(8):105544. doi: 10.1016/j.esmoop.2025.105544. Epub ahead of print. PMID: 40795788.

Tags: Bladder cancer, enfortumab vedotin, Hematology/Oncology, metastatic urothelial carcinoma, pembrolizumab, Phase III, Publications, subgroup analysis

“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and reality

Sedrak MS, Ramalingam SS, Sparano JA. "Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and reality. Cancer. 2026 Jul 1;132(13):e70499.[...]

Case Report: A case of HIV seroconversion in a high-risk individual after 35 years of resistance with a CCR5DELTA32 heterozygous genotype

Aziz N, Kim EY, Jamieson BD, Mimiaga MJ, Martinez J, Detels R. Case Report: A case of HIV seroconversion in a high-risk individual after 35[...]

Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer

Tsvetkova O, Gil TE, Kassir G, Castanon S, Kollapaneni SS, Han A, Park SJ, Li R, Velez MA, Lisberg AE. Evaluating datopotamab deruxtecan (Dato-DXd) as[...]